Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
about
Molecular and cell-based therapies for muscle degenerations: a road under constructionMetabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular DystrophyTaurine: the appeal of a safe amino acid for skeletal muscle disordersPre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overviewThe different impact of a high fat diet on dystrophic mdx and control C57Bl/10 miceIncreased taurine in pre-weaned juvenile mdx mice greatly reduces the acute onset of myofibre necrosis and dystropathology and prevents inflammation.Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agentsLevels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy.What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx miceThe beneficial effects of taurine to counteract sarcopenia.Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.Beneficial effects of high dose taurine treatment in juvenile dystrophic mdx mice are offset by growth restriction.ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies.Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice.Benefits of Prenatal Taurine Supplementation in Preventing the Onset of Acute Damage in the Mdx Mouse.The effect of taurine and β-alanine supplementation on taurine transporter protein and fatigue resistance in skeletal muscle from mdx mice.
P2860
Q24568176-4D590F49-BE69-4C6C-BE59-F41A3BCBC92DQ26772002-6D3DD8C4-5A33-485F-9D2E-BA586B36CDA2Q26799770-B55401AB-4BAF-415B-AC40-CEF5C2EDEB23Q26849430-542C7B49-E6FD-4892-A16F-A1B2B7AEB644Q34077151-FDB37108-2A1E-49E5-BC93-5041AFBB3680Q36146630-3DA14DBB-BD0D-4B4C-8CBC-2C5C857A372BQ36925191-0B2FA61C-1CFF-4AC6-97DF-152505AA9A6AQ37246026-B97993C7-1722-4B97-B6E1-51AAD6703DF7Q38351283-5039919C-19BB-4B18-A98E-91F34810DC9CQ38603674-15276064-C9FF-4D10-9D15-8DCD84FE7F99Q39016892-C042A3B8-20D5-4816-BA26-C6AFC496DDDBQ40219200-A36CFA74-9F9C-48BB-8C8C-93E2CEAE3AE3Q43845526-47D46992-732A-4E01-9DC7-80B8BF97C680Q45871995-B93EE233-A5DD-4812-A304-02ADFDE708C0Q46463712-4E5D7563-96F7-43F0-AD6E-5678CC316B6BQ47349229-75002C80-2DFA-4718-A3AB-FB92F8726F5AQ51625827-A431CA2E-9A93-4E73-BB60-43A3127CF584
P2860
Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Evaluation of potential synerg ...... f Duchenne muscular dystrophy.
@en
Evaluation of potential synerg ...... f Duchenne muscular dystrophy.
@nl
type
label
Evaluation of potential synerg ...... f Duchenne muscular dystrophy.
@en
Evaluation of potential synerg ...... f Duchenne muscular dystrophy.
@nl
prefLabel
Evaluation of potential synerg ...... f Duchenne muscular dystrophy.
@en
Evaluation of potential synerg ...... f Duchenne muscular dystrophy.
@nl
P2093
P2860
P1476
Evaluation of potential synerg ...... of Duchenne muscular dystrophy
@en
P2093
R F Capogrosso
S Simonetti
V T Sblendorio
P2860
P304
P356
10.1111/J.1365-2990.2010.01106.X
P577
2011-04-01T00:00:00Z